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Abstract
Purpose Previous work suggests that opioid users have
lower health-related quality of life (HRQOL) than patients
with more prevalent chronic illnesses such as hypertension
or diabetes. Although comparisons with population norms
are informative, studies of the correlates of HRQOL for
opioid users are needed to plan clinical services.
Methods We tested a conceptual model of the pathways
between physiologic factors and symptoms in relation to
HRQOL among 344 opioid users in a clinical trial. Physical
and mental HRQOL were measured by the Short-Form
(SF)-36; withdrawal signs, symptoms, and functioning
were also measured with validated instruments. Using
structural equation modeling, we tested hypotheses that
medical history directly predicts withdrawal signs and
symptoms, and that medical history, withdrawal signs and
symptoms, and functioning predict the physical and mental
HRQOL latent variables of the SF-36.
Results Most hypothesized relationships were signiﬁcant,
and model ﬁt was good. The model explained 36% of the
variance in mental HRQOL and 34% of the variance in
physical HRQOL.
Conclusions The conceptual framework appears valid for
explaining variation in the physical and mental HRQOL of
opioid users undergoing medically managed withdrawal.
Analysis of longitudinal data would help to evaluate more
rigorously the adequacy of the model for explaining
HRQOL in opioid withdrawal.
Keywords Opiate dependence  Quality of Life 
Models, Structural  Trials, Randomized clinical
Introduction
Opioid dependence is a chronic disorder with multi-faceted
negative medical, psychological, and social consequences
[1]. Outcomes of treatment for opioid dependence include
reductions or cessation in opioid use, typically assessed via
self-reported drug use and laboratory tests for opioid
metabolites in urine. But increasingly there have been calls
for the development of additional outcome measures to
capture treatment-related changes in the medical, psycho-
logical, and social domains impacted by addiction [2].
Patient reports of their functioning and well-being—i.e.,
their health-related quality of life (HRQOL)—are used
increasingly as outcome measures in the evaluation of care
for chronic disorders [3], and measures of HRQOL are
strong predictors of mortality, disease complications, and
resource use [4]. As a result, measures of HRQOL may
provide an important tool for assessing outcomes of treat-
ment for opioid dependence.
The Short-Form 36 (SF-36) is the most widely admin-
istered HRQOL instrument in health outcomes research
[5]. The SF-36 measures aspects of health relevant for
adults in general, allowing for comparisons between
patients with a wide range of health problems [6–12]. In a
number of studies, opioid users in treatment and commu-
nity settings have had consistently lower average SF-36
scores, compared with both the general population and the
patients with serious chronic illnesses such as diabetes and
hypertension [13–21, 23, 24]. For example, an Australian
study of symptom-triggered taper methods for benzodiaz-
epine withdrawal found that patients scored substantially
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ulation [21]. Compared with U.S. data on patients with
serious medical conditions, opioid users in a Canadian
methadone program had lower SF-36 scores on social
functioning, emotional well-being, energy/vitality, and role
limitations due to emotional health problems [22].
Comparisons of HRQOL between opioid-dependent
patients and the general population are informative; how-
ever, studies of the clinical determinants of HRQOL spe-
ciﬁcally among these patients are also needed for planning
and evaluating detoxiﬁcation and other treatment pro-
grams. A study in North Carolina examined determinants
of HRQOL in a convenience sample of active injection
drug users, 82% of whom reported recent heroin use.
Results from eight multiple regression models—one for
each of the eight SF-36 scales—identiﬁed negative asso-
ciations of HRQOL with self-reports of harmful drinking,
heroin use, and methamphetamine use [23].
In this study, we test a conceptual framework of the
direct and mediated pathways between HRQOL, addiction
severity, withdrawal symptoms, and physiologic factors
among patients in treatment for opioid dependence. The
evaluation of such a framework is important for identifying
relationships between clinical variables and HRQOL that
can be used to guide treatment and optimize outcomes for
this patient population. We hypothesized that worse with-
drawal symptoms and addiction severity within our patient
population would predict the reports of poorer physical and
mental HRQOL (Fig. 1).
Methods
Participants
We analyzed baseline data on 344 subjects in a multi-
center trial of buprenophrine conducted in the National
Institute on Drug Abuse Clinical Trials Network (CTN).
Recruitment was conducted from January 2001 to February
2002. Eligible individuals were at least 18 years old, met
diagnostic criteria for opioid dependence, and needed
medical management for withdrawal. Exclusion criteria
included serious medical or psychiatric conditions that
would make participation hazardous, as well as pregnancy,
current lactation, and plans to become pregnant. A total of
113 inpatients and 231 outpatients participated at any of 12
community-based treatment programs in the CTN. Further
details on study design and implementation are available
elsewhere [24]. Our secondary analyses of these public use
data were exempted from review by the Institutional
Review Board at the Charles Drew University of Medicine
and Science.
Conceptual framework
The Wilson and Cleary model positions overall quality of
life at the endpoint of a multi-level continuum, with a
domain of physiologic variables as the starting point [25].
The physiologic domain includes the type of clinical
information gathered in laboratory tests, physical examin-
ations, and medical histories. Physiologic factors are
hypothesized to inﬂuence a domain of signs and symptoms,
which refer, respectively, to clinicians’ observations and
patients’ perceptions of abnormal physical, emotional, and
cognitive states. Signs and symptoms directly predict
functioning, which in turn predicts general health percep-
tions and ﬁnally overall quality of life. In this analysis, we
modiﬁed the Wilson–Cleary model so that general health
perceptions were represented by physical and mental
health. Although the main causal relationships in this
framework are hypothesized to exist between adjacent
domains (e.g., physiologic factors and symptoms), it is also
possible for domains to exert direct effects on nonadjacent
domains (e.g., physiologic factors and functioning).
Because we did not include a measure of overall quality of
life in this study, we were unable to examine the end of the
continuum in the analysis.
Measures
Five of the constructs in our modiﬁcation of the Wilson–
Cleary model are represented as latent variables: physical
Physiologic
Variables
Symptoms
Addiction-Related
Functioning
Physical
Health
Mental
Health
Fig. 1 Conceptual framework
(schematic) linking clinical
variables and health-related
quality of life. HRQOL, health-
related quality of life.
Reference: Wilson and Cleary
[25]
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observed), opioid withdrawal symptoms (patient reported),
and addiction severity. A latent variable is an underlying
unobserved construct that is indicated by two or more
measured variables [26]. The latent variables in this anal-
ysis were created from multi-item scales described below.
Self-reported physical and mental health
The physical and mental health latent variables were
deﬁned by the eight scales of the SF-36 V.1. Four scales
are associated primarily with physical health, and four
scales are associated primarily with mental health. Previous
research indicates that the SF-36 indicators of physical and
mental health are positively correlated [27]. We calculated
the eight SF-36 scale scores for (1) physical health: phys-
ical functioning (ten items); role limitations due to physical
health problems (four items); bodily pain (two items); and
general health perceptions (ﬁve items); and (2) mental
health: social functioning (two items); emotional well-
being (ﬁve items); role limitations due to emotional prob-
lems (three items); and energy/fatigue (four items). Twenty
items use a ‘‘past 4 weeks’’ recall period, and 15 items do
not have a recall period; the ‘‘health transition’’ item is not
used in scoring any of the eight scales. Each of the eight
scale scores were scored with a T-score metric using 1998
U.S. general population means and standard deviations
(mean = 50, SD = 10) [28]. The scale scores were then
allowed to load on two factors representing physical and
mental health.
Adjective rating scale of withdrawal (ARSW)
Baseline opioid withdrawal symptoms were assessed using
the ARSW [29]. Patients rated themselves on response
scales ranging from 0 (‘‘none’’) to 9 (‘‘severe’’) for the
following 16 signs and symptoms of withdrawal: muscle
cramps, depressed or sad, painful joints, excessive yawn-
ing, hot or cold ﬂashes, trouble getting to sleep, nausea,
irritability, runny nose, poor appetite, weak knees, exces-
sive sneezing, tense and jittery, watery eyes, abdominal
cramps, and ﬁtful sleep. With such a broad range of scores,
we assumed an underlying continuous distribution of this
variable. Because of the high coefﬁcient alpha among these
indicators (.96), and to avoid too many indicators for the
size of the patient sample, the 16 items were randomly
combined into four ‘‘parcels’’ [30]. For this variable, a
‘‘parcel’’ refers to an average of the responses of four
randomly selected ARSW items; thus, we included four
parcels, each containing four of the 16 ARSW items, in the
model. Parceling is acceptable in structural modeling when
alpha coefﬁcients are high [31] and when sets of items are
sufﬁciently unidimensional so that important features of
individual items are not discarded when they are combined
[32]. In this sample, coefﬁcient alpha was exceptionally
high (.96). Parceling typically results in better model ﬁt
than do models using individual items with their attendant
measurement error. Models were also tested without par-
celing and were highly similar to those reported in this
article. However, due to the sample size, they are not
presented because they had too many parameters to be
estimated reliably.
Clinical opiate withdrawal scale (COWS)
Baseline opioid withdrawal signs were assessed using the
COWS. The COWS is an 11-item instrument designed to
provide a description of the following signs and symptoms
of withdrawal that can be directly observed by a physician
interviewer: increased resting pulse rate, gastrointestinal
upset, sweating, tremor (observation of outstretched
hands), restlessness, yawning, pupil size (extent of dila-
tion), anxiety or irritability, arthralgias, piloerection of
skin, and runny nose or tearing (not accounted for by cold
symptoms or allergies). Responses to the 11 items are
summed to construct a COWS score that can range from 0
to 48, with higher scores indicating greater withdrawal
severity [33]. Due to considerations cited above, the 11
items were randomly combined into four parcels (coefﬁ-
cient alpha = .77). Three of the parcels consisted of three
items, and one parcel consisted of two items.
Addiction severity index (ASI) lite psychiatric
and family/social scales
The ASI Lite was developed to assess patient functioning
in seven problem areas commonly affected by substance
use disorders. To represent the functioning domain of the
Wilson–Cleary framework for this patient population, we
used the Psychiatric and Family/Social scales of the
instrument. Composite scores for problems in each of these
two domains in the previous 30 days were calculated using
procedures described by McGahan and colleagues [34].
The Psychiatric composite score includes 11 items
assessing aspects of current psychiatric status and func-
tioning such as hallucinations; ‘‘serious anxiety or ten-
sion;’’ and cognitive dysfunction (‘‘trouble understanding,
concentrating, or remembering’’). The Family/Social
composite score is primarily a measure of psycho-social
functioning. It includes ﬁve items assessing the presence of
conﬂict with family, friends, co-workers, neighbors, and
others; the respondent’s satisfaction with his or her current
marital/relationship status, and the degree to which
the respondent was ‘‘troubled or bothered’’ by family
problems.
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Opioid-dependent patients are likely to differ in their
underlying risks for severe withdrawal signs and symp-
toms, resulting from factors such as the presence of coex-
isting conditions and medical history. For this reason, we
included data from the CTN baseline medical history and
physical examination; the ﬁndings of which were recorded
on standardized reporting forms by the clinician conduct-
ing the histories and examinations. We created a count
variable by summing the total number of health conditions
that clinicians elicited from patients during medical his-
tory-taking, from a list of 17 conditions affecting organs or
organ systems such as the eyes, ears, nose and throat; the
cardiovascular system; the integumentary system; and the
liver. We created another count variable representing the
total number of abnormal ﬁndings from a physical exam,
from a list of 17 organ systems and body parts such as the
abdomen, lymph nodes, lungs, pelvis, and genitalia.
Because a recent study showed an association between
HRQOL and body mass index (BMI) [35], we also inclu-
ded patient BMI in the physiologic domain of the model.
Hypotheses
We hypothesized that BMI, abnormal physical exam
ﬁndings, and medical history would predict variation in
withdrawal signs and symptoms—which, in turn, were
hypothesized to predict functioning as measured by the
ASI Psychiatric and Family/Social scales. Signiﬁcant cor-
relations were hypothesized between physical exam ﬁnd-
ings and medical history. Finally, we hypothesized that the
ARSW, COWS, ASI scales, and medical history would
predict self-reported physical and mental health.
Statistical analysis
We used the EQS 6 structural equation modeling (SEM)
program [36], which compares a proposed hypothetical
model with a set of actual data. The closeness of the var-
iance–covariance matrix implied by the hypothetical model
to the empirical data was evaluated using the maximum
likelihood chi-squared statistic (ML v
2) and two goodness-
of-ﬁt indices: The comparative ﬁt index (CFI) and the Root
Mean Square Error of Approximation (RMSEA). Com-
parative ﬁt index values of .95 or greater are desirable and
indicate good ﬁt. The RMSEA is a measure of lack of ﬁt
per degrees of freedom, controlling for sample size. Values
for the RMSEA less than .06 indicate a close-ﬁtting model
[37]. Robust statistics (Robust CFI and Satorra-Bentler v
2)
correcting for multivariate non-normality were also
examined, because the multivariate kurtosis estimate was
high (Mardia’s normalized estimate = 12.96). We also
report the Yuan-Bentler residual-based chi-square statistic,
which performs well in small samples when robust statis-
tics are more appropriate [38, 39].
Due to the continuous and broad variations in most of
the data, we assumed a continuous underlying distribution
in our choice of statistical methods. Nonsigniﬁcant paths
and covariances were incrementally dropped until only
signiﬁcant paths and covariances remained. To improve
model ﬁt, we examined the results of the Lagrange Mul-
tiplier (LM) Test, which suggests additional signiﬁcant
parameters to be added to the model [40]. Indirect effects
were also assessed [41].
Results
Table 1 provides sociodemographic information for the
study sample. Table 2 reports summary statistics for all
variables included in the model and factor loadings of the
indicators for the latent variables in the conﬁrmatory factor
analysis (CFA). Table 3 reports correlations among the
variables in the CFA before the hypothesized directional
path model was tested. The CFA tested the viability of the
proposed factor structure of the latent variables and pro-
vided correlations among components of the model. As
expected, the physiologic and symptom variables generally
had stronger associations with the physical health score
than with the mental health score (Table 3).
Theﬁnalpredictivestructuralequationmodelispresented
in Fig. 2. Measured variables are depicted in rectangles and
the latent variables are in circles. Most hypothesized rela-
tionships were signiﬁcant. One reasonable supplementary
relationshipsuggestedbytheLMTestwasaddedtoimprove
model ﬁt, i.e., a correlated residual between emotional well-
being and energy/fatigue (r = .43). Model ﬁt was good: ML
v
2 = 379.37, 176 df; CFI = .95, RMSEA = .06; Satorra-
Bentler Robust v
2 = 356.19, 176 df; RCFI = .95,
RMSEA = .056; Yuan-Bentler v
2 = 217.24. This model
Table 1 Sociodemographic characteristics of opioid-dependent
patients (n = 344)
%( n) Mean (SD)
Race
African-American/Black 30.9 (106) –
Hispanic/Latino 18.7 (64) –
White 45.2 (155) –
Other 5.3 (18) –
Female gender 32.5 (111) –
Age – 37.9 (10.2)
Years of formal education – 12.5 (1.9)
Income ($), all sources, past 3 months – 1732.9 (1938.3)
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123Table 2 Descriptive statistics, internal consistency estimates, and factor loadings for health-related characteristics of opioid-dependent patients
(n = 344)
Mean (SD) Alpha Loading
Health-related quality of life
Physical Health (SF-36 T scores)
Physical functioning 50.3 (9.0) 0.91 0.73
General health perceptions 44.7 (9.7) 0.75 0.71
Bodily pain 47.1 (12.0) 0.86 0.82
Role limitations due to physical health problems 44.6 (12.3) 0.90 0.73
Mental Health (SF-36 T scores)
Emotional well-being 38.4 (12.1) 0.81 0.80
Social functioning 38.7 (12.2) 0.76 0.88
Energy/fatigue 44.1 (10.5) 0.81 0.72
Role limitations due to emotional problems 39.5 (14.2) 0.89 0.74
Withdrawal signs and symptoms
ARSW ‘‘Parcel 1’’
a 3.4 (2.6) – .92
ARSW ‘‘Parcel 2’’
a 3.5 (2.7) – .90
ARSW ‘‘Parcel 3’’
a 3.2 (2.6) – .93
ARSW ‘‘Parcel 4’’
a 3.3 (2.7) – .95
COWS ‘‘Parcel 1’’
b 0.51 (0.47) – .61
COWS ‘‘Parcel 2’’
b 0.68 (0.66) – .76
COWS ‘‘Parcel 3’’
b 0.72 (0.94) – .60
COWS ‘‘Parcel 4’’
b 0.56 (0.54) – .80
Functioning
ASI family/social composite score 0.14 (0.18) .63 .55
ASI psychiatric composite score 0.18 (0.19) .80 .81
Physiologic factors
Count of abnormal ﬁndings on physical exam 1.2 (1.3) – –
Count of positive ﬁndings from medical history 2.1 (2.2) – –
Body mass index 25.2 (4.8) – –
ARSW, adjective rating scale of withdrawal; ASI, addiction severity index; COWS, clinical opiate withdrawal scale; HRQOL, health-related
quality of life; SF-36, short-form 36
a The 16 items of the ARSW were randomly combined into ‘‘parcels’’ to obtain mean indicators
b The 11 items of the COWS were randomly combined into ‘‘parcels’’ to obtain mean indicators
Table 3 Correlations among variables in the conﬁrmatory factor analysis (CFA)
1. 2. 3. 4. 5. 6. 7. 8.
1. BMI –
2. Exam ﬁndings .09 –
3. Medical history .01 .31*** –
4. Withdrawal Signs -.07 .02 .22*** –
5. Withdrawal Symptoms -.16** -.03 .28*** .56*** –
6. ASI Psych-Family .04 .14* .19** .15* .23*** –
7. Physical HRQOL .00 -.19*** -.35*** -.28*** -.49*** -.32*** –
8. Mental HRQOL .04 -.14* -.26*** -.19** -.31*** -.55*** .84*** –
* p B .05, ** p B .01, *** p B .001. Withdrawal signs assessed with COWS, Clinical Opiate Withdrawal Scale. Withdrawal symptoms
assessed with ARSW, Adjective Rating Scale of Withdrawal. ASI Psych-Family, Addiction severity index psychiatric and family functioning
scales; BMI, body mass index; HRQOL, health-related quality of life
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variance in physical health.
The structural equation model identiﬁed a number of
indirect and direct effects among variables representing the
domains of the conceptual model, going from the physio-
logic level to physical and mental HRQOL (i.e., from left
to right in Fig. 2). Among the direct effects, a greater BMI
predicted fewer withdrawal symptoms. A greater number
of health conditions taken from medical histories predicted
more withdrawal signs and symptoms, as well as lower
physical health and mental health. A greater number of
abnormal ﬁndings from physical exams predicted lower
physical health and more impaired functioning on the ASI
scales. Withdrawal signs were strongly associated with
withdrawal symptoms (r = .56 in the CFA) but did not
independently predict any of the variables further along the
continuum of the conceptual framework; further, its inﬂu-
ence was attenuated by its association with withdrawal
symptoms (which did strongly predict a higher ASI, and
lower QOL measures). Finally, the psychiatric and family/
social functioning scales of the ASI latent variable pre-
dicted lower physical and mental health.
Signiﬁcant indirect effects inﬂuencing variables through
their effects on the intermediate predictors include a sig-
niﬁcant negative indirect effect of BMI on ASI (p\.05)
and a positive effect of a poor medical history on ASI
(p\.01). These effects were mediated through withdrawal
symptoms—which, in turn, predicted ASI. Indirect effects
also had an impact on the physical and mental health latent
variables. Physical health was indirectly impacted by BMI
(positive, p\.01), and negatively by a poor medical his-
tory (p\.001) through their inﬂuence on withdrawal
symptoms. Withdrawal symptoms (p\.05) also had a
signiﬁcant indirect effect mediated through ASI. Mental
health was impacted indirectly by BMI (positively,
p\.01) and poor medical history (negatively, p\.001)
through withdrawal symptoms. Abnormal physical exam
ﬁndings (p\.05) and withdrawal symptoms (p\.001)
negatively impacted mental health through their inﬂuence
on ASI. These inﬂuences can be traced on Fig. 2.
Discussion
A number of studies have used the Wilson–Cleary frame-
work to analyze data on patients with conditions as diverse
as xerostomia [6], HIV disease [7, 8], heart disease [9, 10],
and Hodgkin’s lymphoma [11]. To our knowledge, no
previous study has used this conceptual framework to
analyze HRQOL among patients with a primary diagnosis
of opioid dependence or any other substance use disorder.
Results from the current study suggest that the modiﬁcation
of the Wilson–Cleary framework evaluated here accounts
for meaningful variation in physical and mental health in
this patient population. Because the baseline CTN data are
cross-sectional, the conceptual framework is not proven by
this analysis; however, the hypothesized relationships
among variables that we speciﬁed are consistent with the
data.
Previous analyses of HRQOL among opioid users have
not been based on an established conceptual framework of
health and a parsimonious theory-based statistical model
such as the one used in the current study. A study of a
predominantly heroin-using sample reported results from
Withdrawal
Symptoms
Body
Mass
Index
Abnormal
PhysicalExam
Findings
Physical
Health
-.51***
.31***
Medical
History
Withdrawal
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Mental
Health
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Measures
Withdrawal
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Addiction-Related
Functioning
Health-Related
Quality of Life
-.13**
-.10*
.15*
.22***
.28***
-.18***
-.13**
.53*** .24***
-.16**
-.39***
-.18**
.86***
Fig. 2 Structural equation model depicting signiﬁcant regression
paths (n = 344). Ovals represent latent variables; rectangles repre-
sent single-item indicators; small circles represent correlated error
terms. Single-headed arrows represent regression coefﬁcients; dou-
ble-headed arrows represent correlations between predictive back-
ground variables and correlations between residuals of dependent
variables. Withdrawal signs were based on physician observation
(with the Clinical Opiate Withdrawal Scale). Withdrawal symptoms
were based on patient report (with the Adjective Rating Scale of
Withdrawal). ASI, addiction severity index (Psychiatric and Family/
Social scales). Regression coefﬁcients are standardized (* p B .05,
** p B .01, *** p B .001)
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123eight multiple regression models of the SF-36 scales, which
raises potential problems with multiple statistical testing
[23]. The physical and mental latent variables have a
number of analytic advantages over a focus on the eight
scales, including generally smaller conﬁdence intervals and
a reduction in the number of statistical comparisons [42].
Greater self-reported withdrawal symptoms predicted
lower HRQOL, directly and via greater addiction severity.
Greater opioid withdrawal symptoms likely reﬂect heavier
opioid use and higher opioid dependence, which may
explain the negative association with HRQOL. In addition,
self-reported withdrawal symptoms were related to
HRQOL, while physician-observed withdrawal signs
(COWS) were not. Since HRQOL taps patients’ subjective
well-being, it may be that patients’ perceptions of with-
drawal severity are more important for HRQOL than
objective assessments of withdrawal via clinicians. The
patient-reported measures may have drawn on both the
sensory aspect of symptoms and the respondent’s emo-
tional responses to them, whereas clinician ratings are
limited to a relatively narrow set of observable patient
behaviors. The decreased physical and mental health
associated with withdrawal symptoms underscore the
importance of treating these symptoms during acute with-
drawal. Approved pharmacologic treatments for opioid
dependence such as buprenorphine and methadone are
effective in reducing illicit opioid use and in relieving
opioid withdrawal symptoms [43, 44] and may improve
HRQOL via reductions in opioid withdrawal symptoms.
An advisory from the Substance Abuse and Mental
Health Services Administration notes that patients often
need monitoring and medical management for symptoms
of ‘‘protracted withdrawal,’’ which refers to the persistence
of substance-speciﬁc withdrawal symptoms for weeks,
months, or even years after the generally expected time-
frame for acute withdrawal has ended [45]. Protracted
symptoms such as fatigue, dysphoria, and unexplained
physical complaints would likely contribute to poorer
physical and mental HRQOL, and may eventually lead
patients to seek relief by returning to substance use. By
adding HRQOL measures to inform ongoing treatment
decisions, clinicians may become more effective at iden-
tifying therapies that improve areas of health that matter
greatly to patients, particularly to those experiencing pro-
tracted withdrawal symptoms. Randomized studies in
general medicine and oncology suggest that the integration
of HRQOL measures into routine practice leads to
improvements in processes of care (for example, physi-
cian–patient communication) [46]; however, to our
knowledge, addiction medicine researchers have not stud-
ied the feasibility and potential beneﬁts of using HRQOL
measures in regular clinic practice. This is a potential area
for future work.
Several limitations of the study should be discussed. The
sample was enrolled in a multi-center study conducted in
the National Institute on Drug Abuse CTN and included
both ambulatory care patients and hospitalized patients; a
study focused solely on patients seen in one of these set-
tings may have generated different results. The generaliz-
ability of clinical trial ﬁndings to opioid users in the
community may be limited; however, the physiologic signs
and symptoms of opioid withdrawal probably do not differ
greatly across these populations. Twenty items of the
SF-36 use a ‘‘past 4 weeks’’ recall period, whereas the
ARSW items use a 24-h recall period—which makes using
the ARSW as a predictor of the PCS and MCS problematic.
However, because one would expect a more ‘‘acute’’ ver-
sion of the SF-36 to be more sensitive to variation in acute
symptoms [47], any bias resulting from differences in
recall periods between the ARSW and SF-36 would likely
be toward the null.
Our sample size of 344 was small for the application of
structural equation modeling, which is why we used the
eight SF-36 V.1 scales instead of the 35 separate items. In
a previous work, the SF-36 energy/fatigue scale has been
allowed to load on both the physical and the mental health
factors [28]; we speciﬁed that this scale load only on the
mental health factor. We also used item parcels for the
ARSW and COWS because of the sample size. We ran an
alternative model without parceling the items for these
scales; however, with 344 subjects and over 100 free
parameters, the results were unreliable; however, for the
alternative model, the ML v
2 statistic was 1135.34 on 665
degrees of freedom, RCFI was .934, and RMSEA was .05.
Although parceling may be justiﬁable if the parceled items
represent a single construct, the technique obscures any
unique information attributable to individual items. If items
represent different facets of the same construct, then
improvements in model ﬁt due to parceling would be
misleading [48]. The statistical procedures used presumed
the indicators (items or parcels) to have a continuous
underlying distribution. We used robust estimators (Robust
CFI and Satorra-Bentler v
2) to allow for distributional
asymmetry in the data; however, these estimators assume
that indicators are measured on an interval scale, and it is
debatable whether ordinal items should be treated as
interval data. More robust estimators could have been
applied if a larger sample had been available. Results must
also be considered in light of the limitations of ﬁtting a
model of a temporal process to cross-sectional data.
Analysis of longitudinal data with cross-lagged panel
designs or latent curve models would help to evaluate more
rigorously the effects of symptoms and other antecedent
variables on HRQOL.
The results from this analysis suggest that physiologic
factors have demonstrable effects on withdrawal symptoms
Qual Life Res (2011) 20:1205–1213 1211
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Current approaches to substance abuse and other psychi-
atric disorders depend greatly on the patient’s reported
experience of illness. The practice of ‘‘measurement-based
care’’ refers to the systematic measurement of symptoms
and side effects at each treatment visit and the use of
guidelines to modify therapy based on patient-reported
measures [49]. Within opioid dependence treatment spe-
ciﬁcally, amelioration of opioid withdrawal symptoms
using available pharmacotherapies such as buprenorphine
or methadone may improve HRQOL in addition to reduc-
ing illicit opioid use. One beneﬁt of using HRQOL
instruments in measurement-based care is that they are
outcomes that are important to patients [50]. Future work
should assess whether opioid dependence treatments that
are informed by the effects of treatment on HRQOL lead to
better outcomes, including increases in patients’ motivation
to engage in longer-term rehabilitation efforts.
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